ARA-290 (Cibinetide) Dosage Guide: Neuropathy, Nerve Repair & Anti-Inflammation Protocol

ARA-290 (Cibinetide)

ARA-290 (Cibinetide) is a non-erythropoietic peptide derived from erythropoietin (EPO), studied for its anti-inflammatory, neuroprotective, and tissue-repair effects without stimulating red blood cell production.

How It Works

Innate Repair Receptor (IRR) Activation → Inflammation ↓ + Nerve Repair ↑ + Tissue Protection ↑

ARA-290 selectively activates the innate repair receptor (IRR), a pathway involved in reducing inflammation, protecting nerve tissue, and promoting cellular repair. Unlike EPO, it does not stimulate hematocrit or red blood cell production.

ARA-290 Protocol

Weeks 1–4

Dose2 mg daily

Units20 units

Volume0.20 mL

Weeks 5–8

Dose2–4 mg daily

Units20–40 units

Volume0.20–0.40 mL

Frequency: Once daily
Timing: Morning or early afternoon
Route: Subcutaneous
Cycle Length: 4–8 weeks

Neuropathy Protocol (Targeted Use)

Weeks 1–4

Dose4 mg daily

Units40 units

Volume0.40 mL

Weeks 5–8

Dose4 mg daily

Units40 units

Volume0.40 mL

Frequency: Once daily
Timing: Morning preferred
Route: Subcutaneous
Cycle Length: 6–8 weeks

• Designed for nerve-related conditions such as small fiber neuropathy
• Consistent daily dosing is key for nerve repair signaling
• Often requires full 6–8 week cycles for noticeable effects
• Can be paired with supportive recovery protocols

When & Where to Inject

• Subcutaneous injection preferred
• Common sites: abdomen, thigh, upper arm
• Rotate injection sites daily
• Use a consistent time each day

Reconstitution & Dosing (10 mg Vial)

Vial 10 mg

Water 1.0 mL

Concentration 10 mg/mL

Conversion 1 unit = 100 mcg

Dose Reference

10 units = 1 mg

20 units = 2 mg

40 units = 4 mg

Reconstitution Steps

Draw 1.0 mL bacteriostatic water

Inject slowly into vial

Gently swirl (do not shake)

Allow full dissolution

Storage

Refrigerate at 2–8°C after reconstitution

Do not freeze after mixing

Use within 30 days

Monitoring During Use

• Nerve pain or neuropathy symptoms
• Inflammation and recovery markers
• Sensation improvements
• General recovery and function

Benefits

• Supports nerve repair and regeneration
• Reduces inflammation
• Studied in small fiber neuropathy
• May improve tissue recovery and healing
• Non-erythropoietic (does not raise hematocrit)

Potential Side Effects

• Mild injection site irritation
• Rare headache or fatigue
• Generally well tolerated in studies

Important Notes

• Does not affect red blood cell production like EPO
• Often discussed for neuropathy and nerve-related conditions
• Works best with consistent daily use
• Research is still emerging

Important Disclaimer

ARA-290 (Cibinetide) is an investigational peptide and is not FDA-approved. This content is for educational and research purposes only.

Peptide Directory →